Back to Search
MYLES PRADOS, MD
MD
Infectious Disease Physician
NPI: 1780147629Individual
Specialties, Licenses & Credentials
Hospitalist Physician
Hospitalist
Code: 208M00000X
41949(AL)
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
41949(AL)
Research & Publications (20)
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
PMID 19075262·J Clin Oncol·2009
3-trial
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
PMID 17694310·Cancer Chemother Pharmacol·2008
3-trial
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
PMID 16443950·Neuro Oncol·2006
3-trial
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
PMID 16533878·Neuro Oncol·2006
3-trial
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
PMID 14769138·Neuro Oncol·2004
3-trial
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
PMID 15001257·Int J Radiat Oncol Biol Phys·2004
3-trial
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
PMID 14769140·Neuro Oncol·2004
3-trial
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.
PMID 12672281·Neuro Oncol·2003
3-trial
Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
PMID 14682377·J Neurooncol·2003
3-trial
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
PMID 11163499·Int J Radiat Oncol Biol Phys·2001
3-trial
Future directions in the treatment of malignant gliomas with temozolomide.
PMID 10866349·Semin Oncol·2000
6-review
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.
PMID 19618114·J Neurooncol·2010
6-review
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
PMID 19585223·J Neurooncol·2010
7-preclinical
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
PMID 19562255·J Neurooncol·2010
3-trial
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.
PMID 19357966·J Neurooncol·2009
8-other
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
PMID 18850068·J Neurooncol·2009
3-trial
A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
PMID 19356859·Int J Radiat Oncol Biol Phys·2009
3-trial
Quality of life in low-grade glioma patients receiving temozolomide.
PMID 18713953·Neuro Oncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 619 19TH ST S
BIRMINGHAM, AL 35233 - Phone
- (205) 934-4011
Quick Facts
- NPI
- 1780147629
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile